Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Non Operating Income (2021 - 2025)

Historic Non Operating Income for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to $58.1 million.

  • SAB Biotherapeutics' Non Operating Income rose 595490.65% to $58.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.9 million, marking a year-over-year increase of 89759.86%. This contributed to the annual value of $8.8 million for FY2024, which is 31379.83% up from last year.
  • As of Q3 2025, SAB Biotherapeutics' Non Operating Income stood at $58.1 million, which was up 595490.65% from -$382209.0 recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Non Operating Income registered a high of $58.1 million during Q3 2025, and its lowest value of -$4.0 million during Q4 2023.
  • Over the past 5 years, SAB Biotherapeutics' median Non Operating Income value was $220605.0 (recorded in 2023), while the average stood at $4.1 million.
  • In the last 5 years, SAB Biotherapeutics' Non Operating Income crashed by 3616802.5% in 2023 and then soared by 1310814.09% in 2024.
  • SAB Biotherapeutics' Non Operating Income (Quarter) stood at -$450448.0 in 2021, then surged by 102.45% to $11043.0 in 2022, then crashed by 36168.02% to -$4.0 million in 2023, then soared by 65.21% to -$1.4 million in 2024, then surged by 4294.11% to $58.1 million in 2025.
  • Its last three reported values are $58.1 million in Q3 2025, -$382209.0 for Q2 2025, and $5.6 million during Q1 2025.